Briefly, with a fall in cardiac output, the sympathetic nervous system and RAAS are activated, resulting in increased levels of circulating norepinephrine and angiotensin II
Monitoring recommendations for safe use: Baseline assessment including mental health history and current medications Gradual dose titration over five weeks to minimise adverse effects Regular follow-up appointments, particularly during the first three months Discontinuation if less than 5% weight loss after 12 weeks on the 3.0 mg dose Patient education about symptoms requiring medical attention Patients should be advised to contact their GP or prescribing clinician if they experience any concerning symptoms
Steinberg GR, Kemp BE
Cost plays a vital role in treatment selection
The affinity ratios embedded in the engineered peptides produce downstream biology that the separate components, dosed independently, do not reproduce
Both the ADA and the AACE agree that the HbA1c goals should be individualized, but despite all the treatment options available, good glycemic control is not always attainable